Age and Outcomes Associated with BP in Patients with Incident CKD

Csaba P. Kovesdy,† Ahmed Alrifai,* Elvira O. Gosmanova,‡§ Jun Ling Lu,* Robert B. Canada,* Barry M. Wall,*† Adriana M. Hung,‖¶ Miklos Z. Molnar,* and Kamyar Kalantar-Zadeh***

Abstract

Background and objectives Hypertension is the most important treatable risk factor for cardiovascular outcomes. Many patients with CKD are elderly, but the ideal BP in these individuals is unknown.

Design, setting, participants, & measurements From among 339,887 patients with incident eGFR<60 ml/min per 1.73 m^2, we examined associations of systolic BP (SBP) and diastolic BP (DBP) with all-cause mortality, incident coronary heart disease (CHD), ischemic strokes, and ESRD from the time of developing CKD until the end of follow-up (July 26, 2013, for mortality, CHD, and stroke, and December 31, 2011, for ESRD) in multivariable-adjusted survival models categorized by patients' age.

Results Of the total cohort, 300,424 (88%) had complete data for multivariable analysis. Both SBP and DBP showed a U-shaped association with mortality. SBP displayed a linear association with CHD, stroke, and ESRD, whereas DBP showed no consistent association with either. SBP>140 mmHg was associated with higher incidence of all examined outcomes, but with an incremental attenuation of the observed risk in older compared with younger patients ($P<0.05$ for interaction) The adjusted hazard ratios and 95% confidence intervals associated with SBP≥170 mmHg (compared with 130–139 mmHg) in patients <50, 50–59, 60–69, 70–79, and ≥80 years were 1.95 (1.34 to 2.84), 2.01 (1.75 to 2.30), 1.68 (1.49 to 1.89), 1.39 (1.25 to 1.54), and 1.30 (1.17 to 1.44), respectively. The risk of incident CHD, stroke, and ESRD was incrementally higher with higher SBP in patients aged <80 years but showed no consistent association in those aged ≥80 years ($P<0.05$ for interaction for all outcomes).

Conclusions In veterans with incident CKD, SBP showed different associations in older versus younger patients. The association of higher SBP with adverse outcomes was present but markedly reduced in older individuals, especially in those aged ≥80 years. Elevated DBP showed no consistent association with vascular outcomes in patients with incident CKD.

Clin J Am Soc Nephrol 11: 821–831, 2016. doi: 10.2215/CJN.08660815

*Division of Nephrology, University of Tennessee Health Science Center, Memphis, Tennessee; †Nephrology Section, Memphis Veterans Affairs Medical Center, Memphis, Tennessee; ‡Nehphrology Section, Straton Veterans Affairs Medical Center, Albany, New York; §Department of Medicine, Albany Medical College, Albany, New York; ‖Nephrology Section, Nashville Veterans Affairs Medical Center, Nashville, Tennessee; ¶Division of Nephrology, Vanderbilt University, Nashville, Tennessee; and **Harold Simmons Center for Chronic Disease Research and Epidemiology, Division of Nephrology and Hypertension, University of California-Irvine, Orange, California

Correspondence: Dr. Csaba P. Kovesdy, Division of Nephrology, Memphis Veterans Affairs Medical Center, 1030 Jefferson Avenue, Memphis, TN 38104. Email: ckovesdy@uthsc.edu

Introduction

Hypertension is the number one cardiovascular risk factor (1), yet its control rates remain suboptimal (2). Hypertension is especially common in the elderly (3).

Observational studies examining the effects of BP in elderly offer conflicting evidence. Some indicate linearly worse outcomes with higher BP (4), whereas others suggest that BP has a J-shaped association with outcomes (5–8) and that high BP has a diminished or reversed association with adverse outcomes in elderly patients. Clinical trials offer some indication that treating elevated BP to moderately low levels may decrease cardiovascular events in very old individuals (9,10), but it remains unclear whether using even stricter targets is beneficial (11,12). The 2014 report from the panel members appointed to the Eighth Joint National Committee recommended less stringent BP treatment in patients >60 years of age and without diabetes or CKD (13). More recently, the Systolic Blood Pressure Intervention Trial (SPRINT) showed lower mortality in patients at high cardiovascular risk, including those with mild-to-moderate CKD (14). Although these results offer much-needed evidence for lowering elevated BP toward more stringent targets, the limited external validity of clinical trials will make it difficult to apply SPRINT results to patients with characteristics different from those of SPRINT participants, such as the very old or those with advanced CKD. Furthermore, the safety of SBP even lower than that used in SPRINT remains unclear.

Patients with CKD are at high risk for the adverse effects of high BP, but most patients with CKD are older and may also be more sensitive to the adverse effects of low BP than individuals with normal kidney function (15–19). Therefore, it would be important to consider age as a factor influencing decisions about BP therapy in patients with CKD. However, despite compelling theoretical consideration, there is no clear evidence to inform about the ideal BP in elderly patients with CKD.

We examined the association of systolic BP (SBP) and diastolic BP (DBP) with all-cause mortality and incidence of CHD, ischemic stroke, and ESRD in 339,887 United States veterans with incident CKD, and we hypothesized that the patients' age would significantly modify the association of BP with these outcomes.

Materials and Methods

Study Design and Participants

Analyses were conducted in a historic cohort study examining risk factors in patients with incident CKD (Racial and Cardiovascular Risk Anomalies in CKD study). Details on cohort definition were previously published (20–22). Briefly, the parent cohort consisted of 3,582,478 patients with eGFR≥60 ml/min per 1.73 m^2, based on serum creatinine measurements performed from October 1, 2004, to September 30, 2006. Our analytic sample for this study consisted of 339,887 patients who, during a median follow-up of 7.6 years after the first eGFR measurement from October 1, 2004, to September 30, 2006, developed incident CKD stages 3A–5 (Supplemental Figure 1), defined as two eGFR values of <60 ml/min per 1.73 m^2 and a decrease of ≥25% from baseline eGFR (23). The Research and Development Committees at the Memphis and Long Beach Veterans Affairs (VA) Medical Centers approved the study protocol.

Sociodemographic Characteristics and Comorbidities

Baseline variables were determined at the date of cohort entry (defined as the date of the eGFR value used to diagnose incident CKD). Information about baseline characteristics was obtained from various national VA research data files, as previously described (24–26). We grouped patients into five mutually exclusive categories based on their baseline age (<50, 50–59, 60–69, 70–79, and ≥80 years). Race was determined by combining information from VA and Medicare sources (27,28). Comorbidities and clinical events were assessed using International Classification of Diseases, Ninth Revision (ICD-9) and Common Procedural Terminology codes (Supplemental Material). We calculated the Charlson comorbidity index (CCI) using the Deyo modification for administrative datasets, without including kidney disease (29), and categorized patients according to the presence or absence of comorbidities besides CKD and hypertension (CCI <1 versus ≥1). In an attempt to examine frailty, we identified patients who lost weight, defined as the presence of weight loss >5% during the 12 months leading up to cohort entry or a baseline body mass index (BMI) <18.5 kg/m^2 (30).

BP and Medication Use

Baseline BP was defined as the average of all outpatient BP measurements during the first 90 days following cohort entry. SBP and DBP were categorized into nine and six groups, respectively (SBP, <100 to ≥170 mmHg in 10-mmHg increments; DBP, <50 to ≥90 mmHg in 10-mmHg increments). Exposure to the number of antihypertensive classes used at baseline was assessed from VA pharmacy records and categorized as none versus one to two versus three or more drugs.

Outcomes

Outcomes of interest were all-cause mortality, incident coronary heart disease (CHD), incident ischemic strokes, and ESRD. Deaths were identified from the VA Vital Status Files, the sensitivity and specificity of which are 98.3% and 99.8%, respectively (31). CHD and stroke were defined as the composite of a first ICD-9 or Current Procedural Terminology code for acute myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting, and for ischemic stroke, following the date of incident CKD in patients without such diagnoses before this date (Supplemental Figure 1). Information on ESRD was obtained from the US Renal Data System.

Statistical Analyses

Data are expressed as means±SDs, medians (interquartile ranges), and proportions and were examined across SBP categories. Patients were followed from cohort entry until death or were censored at the date of the last encounter, or on July 26, 2013, for mortality (median follow-up, 4.8 years), CHD (median follow-up, 4.9 years), and stroke (median follow-up, 4.8 years), and December 31, 2011, for ESRD (median follow-up, 3.8 years).

The association of SBP and DBP with outcomes was examined in crude and adjusted Cox models. Models were adjusted on the basis of *a priori* considerations for baseline age, sex, race, marital status, per capita income, eGFR, prevalent comorbidities (hypertension, diabetes mellitus, coronary artery disease, congestive heart failure, cerebrovascular disease, peripheral artery disease, malignancies, liver disease, rheumatologic diseases, chronic lung disease, dementia, HIV/AIDS, depression, weight loss or low BMI, and CCI), number of antihypertensive medications, and DBP or SBP. A total of 300,424 patients (88% of the total sample) had complete data for analysis. Because of the relatively low proportion of missingness, these values were not imputed. Sensitivity analyses were performed in subgroups divided by CCI of <1 versus ≥1 and the presence or absence of weight loss or low BMI. Interactions were examined by inclusion of multiplicative interaction terms for SBP/DBP and age, accounting for nonlinear associations (32). Statistical analyses were performed using Stata MP software, version 12 (StataCorp., College Station, TX).

Results

The mean±SD age of the cohort at baseline was 69.2±10.4 years, 96.8% of patients were men, and the mean baseline eGFR was 48±9 ml/min per 1.73 m^2. Baseline characteristics of the overall cohort, and of patients categorized by their baseline SBP, are shown in Table 1. Patients with higher SBP were more likely to be black and to have diabetes mellitus and hypertension and less likely to have CHD, congestive heart failure, and chronic lung disease. Comorbidities were common in all SBP groups, but the proportion of patients with CCI≥1 and with weight loss or low BMI was highest in those with the lowest SBP. Most patients received at least one antihypertensive medication, including 91% of patients with SBP<100 mmHg.

Table 1. Baseline characteristics

Variable	Overall (*N*=339,887)	Systolic BP								
		<100 mmHg (*n*=8712)	100–109 mmHg (*n*=22,474)	110–119 mmHg (*n*=53,318)	120–129 mmHg (*n*=80,073)	130–139 mmHg (*n*=90,361)	140–149 mmHg (*n*=48,010)	150–159 mmHg (*n*=22,370)	160–169 mmHg (*n*=9070)	≥170 mmHg (*n*=5499)
Age, yr	69±10	70±11	68±11	69±11	69±10	70±10	69±10	69±10	69±11	68±11
Men	328,918 (97)	8490 (97)	21,743 (97)	51,504 (97)	77,400 (97)	87,513 (97)	46,491 (97)	21,673 (97)	8813 (97)	5291 (96)
Race										
White	254,068 (79)	6826 (83)	17,623 (82)	41,164 (81)	60,879 (80)	67,693 (79)	34,634 (76)	15,707 (74)	6094 (71)	3448 (66)
Black	54,852 (17)	1084 (13)	3042 (14)	7506 (15)	12,003 (16)	13,956 (16)	8,986 (20)	4649 (22)	2127 (25)	1499 (29)
Hispanic	7834 (2)	159 (2)	436 (2)	1156 (2)	1808 (2)	2156 (3)	1190 (3)	546 (3)	234 (3)	149 (3)
Other	5843 (2)	159 (2)	390 (2)	919 (2)	1376 (2)	1534 (2)	829 (2)	382 (2)	150 (2)	104 (2)
Marital status										
Married	181,870 (55)	4714 (56)	11,696 (54)	27,919 (54)	42,896 (55)	49,949 (57)	25,526 (55)	11,782 (54)	4730 (54)	2658 (50)
Single	24,186 (7)	649 (8)	1785 (8)	4016 (8)	5711 (7)	5,878 (7)	3457 (7)	1602 (7)	659 (8)	429 (8)
Divorced	83,163 (25)	2088 (25)	5735 (26)	13,662 (26)	19,685 (25)	20,783 (24)	11,749 (25)	5586 (26)	2312 (26)	1563 (29)
Widower	39,806 (12)	991 (12)	2496 (12)	6010 (12)	9076 (12)	10,943 (13)	5803 (12)	2724 (13)	1089 (12)	674 (13)
eGFR, ml/min per 1.73 m^2	48±9	47±9	48±9	48±9	48±9	48±9	48±9	48±9	48±8	48±8
BMI, kg/m^2	30±6	28±6	29±6	30±6	30±6	30±6	30±6	30±6	30±6	30±7
Weight loss or low BMI	53,980 (17)	2083 (26)	5048 (24)	10,366 (21)	13,453 (18)	12,307 (15)	6229 (14)	2772 (13)	1079 (13)	643 (13)
Per capita income, US$	22,097 (12,103–33,029)	22,616 (12,305–33,757)	21,939 (11,851–32,477)	21,917 (12,007–32,592)	22,209 (12,118–33,004)	22,841 (12,369–33,953)	21,889 (12,124–32,837)	21,143 (11,876–32,665)	20,271 (11,722–32,363)	19,339 (11,276–31,455)
Systolic BP, mmHg	131±16	95±5	106±3	115±3	125±3	135±3	145±3	155±3	164±3	180±10
Diastolic BP, mmHg	71±10	57±7	62±7	66±8	70±8	73±9	76±9	80±10	83±11	89±13
Hypertension	296,490 (87)	6683 (77)	17,810 (79)	43,926 (82)	68,798 (86)	80,463 (89)	44,061 (92)	20,913 (93)	8573 (95)	5263 (96)
Diabetes mellitus	167,568 (49)	3800 (44)	10,323 (46)	25,231 (47)	38,989 (49)	44,554 (49)	24,600 (51)	11,980 (54)	5029 (55)	3062 (56)
Coronary heart disease	135,091 (40)	4785 (55)	11,381 (51)	23,890 (45)	32,236 (40)	33,566 (37)	16,754 (35)	7790 (35)	3039 (34)	1650 (30)
Congestive heart failure	52,738 (16)	2904 (33)	6431 (29)	11,075 (21)	12,164 (15)	10,684 (12)	5486 (11)	2486 (11)	944 (10)	564 (10)
Stroke	38,318 (11)	974 (11)	2527 (11)	6053 (11)	9002 (11)	9864 (11)	5449 (11)	2719 (12)	1101 (12)	629 (11)
Peripheral artery disease	16,309 (5)	398 (5)	1087 (5)	2649 (5)	3807 (5)	4114 (5)	2371 (5)	1158 (5)	479 (5)	246 (4)
Chronic lung disease	95,745 (28)	2844 (33)	7591 (34)	17,116 (32)	23,819 (30)	23,938 (26)	12,158 (25)	5245 (23)	1973 (22)	1061 (19)
Dementia	5054 (1)	141 (2)	324 (1)	841 (2)	1316 (2)	1311 (1)	674 (1)	284 (1)	115 (1)	48 (1)
Rheumatologic disease	7980 (2)	221 (3)	582 (3)	1375 (3)	2022 (3)	2052 (2)	1020 (2)	476 (2)	155 (2)	77 (1)
Liver disease	8475 (2)	362 (4)	1217 (5)	1896 (4)	2055 (3)	1607 (2)	823 (2)	323 (1)	117 (1)	75 (1)
Malignancies	62,843 (18)	1425 (16)	4138 (18)	10,220 (19)	15,483 (19)	16,787 (19)	8780 (18)	3860 (17)	1381 (15)	769 (14)
AIDS/HIV	3010 (0.9)	85 (1)	272 (1)	673 (1)	750 (0.9)	639 (0.7)	349 (0.7)	148 (0.7)	63 (0.7)	31 (0.6)
Depression	38,279 (11)	956 (11)	2951 (13)	7114 (13)	9673 (12)	9533 (11)	4873 (10)	2019 (9)	713 (8)	447 (8)
CCI≥1	203,090 (60)	5961 (69)	15,256 (68)	33,899 (64)	48,320 (60)	51,420 (57)	27,363 (57)	12,781 (57)	5122 (57)	2968 (54)
Number of antihypertensive medications										
0	28,150 (8)	770 (9)	2019 (9)	5079 (10)	7263 (9)	7513 (8)	3384 (7)	1369 (6)	459 (5)	294 (5)
1–2	129,981 (38)	2745 (32)	7854 (35)	20,534 (39)	32,142 (40)	36,324 (40)	18,141 (38)	7790 (35)	2939 (32)	1512 (28)
≥3	181,756 (53)	5197 (59)	12,601 (56)	27,705 (52)	40,668 (51)	46,524 (51)	26,485 (55)	13,211 (59)	5672 (63)	3693 (67)

Data are presented as mean±SD, medians (interquartile ranges), or number (% of total). Weight loss or low body mass index (BMI) defined as a decrease in weight of >5% in the last 12 months before baseline or a BMI<18.5 kg/m^2 at baseline. CCI, Charlson comorbidity index.



Figure 1. | Association of systolic BP (SBP) and diastolic BP (DBP) with all-cause mortality, among 300,424 patients with incident CKD of different ages, in multivariable-adjusted Cox models. Models were adjusted for age, sex, race, marital status, per capita income, eGFR, prevalent comorbid conditions (hypertension, diabetes mellitus, coronary heart disease, congestive heart failure, peripheral artery disease, malignancies, liver disease, rheumatologic diseases, chronic lung disease, dementia, HIV/AIDS, depression, weight loss, and Charlson comorbidity index), number of antihypertensive medications prescribed at baseline, and baseline DBP (for SBP analyses) and baseline SBP (for DBP analyses). 95% CI, 95% confidence interval.

Mortality

A total of 100,763 patients died (63.0 deaths/1000 patient-years [PY]; 95% confidence interval [95% CI], 62.6 to 63.4) during a median follow-up of 4.8 years (range, 0.2–8.8 years), and mortality rates were higher in older patients in all SBP categories. Age modified the association of SBP with mortality (P for interaction <0.001). Compared with an SBP of 130–139 mmHg, SBP≥140 mmHg was associated with higher crude mortality rates in all age groups, but with attenuation of these differences in older patients (Supplemental Figure 2, Supplemental Table 1). The same pattern was evident in multivariable Cox models: The adjusted hazard ratio (aHRs) associated with SBP≥170 mmHg (compared with 130–139 mmHg) in patients aged <50, 50–59, 60–69, 70–79, and ≥80 years were 1.95 (95% CI, 1.34 to 2.84), 2.01 (95% CI, 1.75 to 2.30), 1.68 (95% CI, 1.49 to 1.89), 1.39 (95% CI, 1.25 to 1.54), and 1.30 (95% CI, 1.17 to 1.44), respectively (Figure 1, Table 2). SBP<120 mmHg was associated with higher mortality in all age groups. The lowest mortality was associated with SBP of 120–139 mmHg in patients <80 years and with SBP of 120–159 mmHg in patients ≥80 years. Lower DBP was also associated with higher mortality in all age groups, with the lowest mortality seen in patients with DBP of 70–79 mmHg in patients <50 years and 80–89 mmHg in patients ≥50 years (Figure 1, Table 3, Supplemental Figure 3, Supplemental Table 2). Results were similar when we examined association in patients without weight loss or low BMI or comorbidities (Supplemental Figures 4 and 5). There was no consistent trend in the associations between SBP or DBP and mortality in any age group among patients who had weight loss or low BMI.

Incident CHD

A total of 9450 patients experienced an incident CHD event (9.8 events/1000 PY; 95% CI, 9.6 to 10.0). Incident CHD rates were similar or lower in older versus younger individuals (Supplemental Tables 1 and 2). Age modified the association of SBP with CHD (P for interaction <0.001). Higher SBP was associated with higher crude CHD rates in patients aged <80 years, with a significant attenuation in the older age groups (Supplemental Figure 2, Supplemental Table 1). Results were similar in multivariable-adjusted Cox models: The aHRs associated with SBP≥170 mmHg (compared with 130–139 mmHg) in patients <50, 50–59, 60–69, 70–79, and ≥80 years were 2.42 (95% CI, 1.26 to 4.66), 1.91 (95% CI, 1.45 to 2.50), 1.39 (95% CI, 1.04 to 1.86), 1.71 (95% CI, 1.27 to 2.29), and 1.36 (95% CI, 0.87 to 2.13), respectively (Figure 2, Table 2). The lowest CHD incidence was associated with SBP<110 mmHg in patients <70 years, and with SBP<140 mmHg in patients ≥70 years. DBP showed no association with CHD. Associations showed a similar pattern when we examined incident CHD in patients without weight loss or low BMI and in those with or without comorbidities (Supplemental Figures 6 and 7). There was no consistent association

Table 2. Multivariable-adjusted hazard ratios and 95% confidence intervals of different outcomes, associated with different systolic BP values in patients of different ages

Outcome per Age Category, yr	Systolic BP							
	<100 mmHg (*n*=8712)	100–109 mmHg (*n*=22,474)	110–119 mmHg (*n*=53,318)	120–129 mmHg (*n*=80,073)	140–149 mmHg (*n*=48,010)	150–159 mmHg (*n*=22,370)	160–169 mmHg (*n*=9070)	≥170 mmHg (*n*=5499)
Mortality								
<50	1.81 (1.31 to 2.51)	1.73 (1.38 to 2.17)	1.23 (1.02 to 1.48)	1.18 (1 to 1.4)	1.14 (0.93 to 1.39)	1.31 (1.01 to 1.69)	2.10 (1.52 to 2.9)	1.95 (1.34 to 2.84)
50–59	1.12 (1 to 1.25)	1.09 (1.01 to 1.18)	1.03 (0.97 to 1.09)	1.01 (0.96 to 1.07)	1.15 (1.08 to 1.22)	1.39 (1.29 to 1.51)	1.62 (1.45 to 1.82)	2.01 (1.75 to 2.30)
60–69	1.16 (1.06 to 1.26)	1.11 (1.04 to 1.17)	1.03 (0.98 to 1.08)	1.00 (0.96 to 1.05)	1.08 (1.03 to 1.13)	1.20 (1.12 to 1.28)	1.54 (1.41 to 1.69)	1.68 (1.49 to 1.89)
70–79	1.21 (1.13 to 1.31)	1.17 (1.11 to 1.24)	1.11 (1.06 to 1.15)	1.04 (1.00 to 1.07)	1.09 (1.04 to 1.13)	1.17 (1.11 to 1.24)	1.28 (1.19 to 1.39)	1.39 (1.25 to 1.54)
≥80	1.25 (1.16–1.36)	1.21 (1.14 to 1.28)	1.12 (1.07 to 1.17)	1.01 (0.98 to 1.05)	1.04 (0.99 to 1.08)	1.06 (1.00 to 1.12)	1.14 (1.05 to 1.24)	1.30 (1.17 to 1.44)
Coronary heart disease								
<50	0.59 (0.18 to 1.97)	0.43 (0.20 to 0.94)	0.79 (0.51 to 1.21)	0.89 (0.62 to 1.29)	1.48 (1.04 to 2.12)	1.49 (0.92 to 2.42)	1.49 (0.77 to 2.87)	2.49 (1.29 to 4.79)
50–59	0.68 (0.48 to 0.96)	0.64 (0.52 to 0.80)	0.76 (0.66 to 0.88)	0.82 (0.73 to 0.93)	1.22 (1.07 to 1.38)	1.57 (1.34 to 1.82)	1.70 (1.37 to 2.10)	1.92 (1.46 to 2.52)
60–69	0.67 (0.48 to 0.94)	0.91 (0.76 to 1.10)	0.83 (0.73 to 0.94)	0.93 (0.83 to 1.03)	1.18 (1.05 to 1.32)	1.3 (1.12 to 1.51)	1.69 (1.38 to 2.07)	1.38 (1.03 to 1.85)
70–79	0.86 (0.58 to 1.26)	0.91 (0.72 to 1.15)	0.97 (0.83 to 1.13)	0.91 (0.80 to 1.04)	1.08 (0.94 to 1.24)	1.36 (1.14 to 1.61)	1.53 (1.21 to 1.94)	1.70 (1.26 to 2.28)
≥80	0.62 (0.34 to 1.12)	0.87 (0.61 to 1.23)	1.05 (0.84 to 1.30)	0.96 (0.80 to 1.15)	1.30 (1.08 to 1.57)	1.23 (0.96 to 1.58)	1.40 (0.99 to 1.99)	1.37 (0.88 to 2.14)
Stroke								
<50	0.27 (0.06 to 1.15)	1.02 (0.60 to 1.74)	1.05 (0.72 to 1.52)	0.99 (0.72 to 1.38)	1.46 (1.04 to 2.04)	1.24 (0.79 to 1.96)	1.84 (1.04 to 3.24)	1.99 (1.05 to 3.79)
50–59	0.54 (0.40 to 0.72)	0.76 (0.64 to 0.90)	0.78 (0.69 to 0.89)	0.93 (0.84 to 1.04)	1.34 (1.20 to 1.50)	1.52 (1.32 to 1.75)	1.86 (1.54 to 2.25)	2.28 (1.82 to 2.86)
60–69	0.67 (0.52 to 0.85)	0.82 (0.71 to 0.95)	0.83 (0.74 to 0.92)	0.90 (0.82 to 0.98)	1.14 (1.04 to 1.26)	1.38 (1.21 to 1.56)	1.56 (1.31 to 1.87)	1.98 (1.59 to 2.46)
70–79	0.67 (0.52 to 0.88)	0.73 (0.61 to 0.86)	0.92 (0.82 to 1.03)	0.91 (0.83 to 1.00)	1.1 (0.99 to 1.22)	1.24 (1.09 to 1.42)	1.59 (1.32 to 1.91)	1.79 (1.41 to 2.27)
≥80	0.59 (0.39 to 0.90)	0.97 (0.77 to 1.22)	0.92 (0.78 to 1.08)	1.12 (0.98 to 1.28)	1.23 (1.07 to 1.43)	1.27 (1.05 to 1.53)	1.38 (1.06 to 1.80)	1.26 (0.89 to 1.79)
ESRD								
<50	0.51 (0.20 to 1.30)	0.42 (0.22 to 0.79)	0.44 (0.29 to 0.67)	0.57 (0.40 to 0.80)	2.06 (1.54 to 2.76)	3.41 (2.46 to 4.73)	4.85 (3.27 to 7.20)	7.49 (4.82 to 11.64)
50–59	0.52 (0.34 to 0.80)	0.48 (0.36 to 0.64)	0.37 (0.30 to 0.46)	0.59 (0.50 to 0.69)	1.70 (1.48 to 1.96)	2.79 (2.40 to 3.25)	4.37 (3.65 to 5.24)	6.04 (4.92 to 7.42)
60–69	0.28 (0.15 to 0.54)	0.52 (0.37 to 0.72)	0.50 (0.40 to 0.64)	0.57 (0.46 to 0.69)	1.51 (1.26 to 1.80)	2.47 (2.02 to 3.02)	3.97 (3.11 to 5.08)	7.08 (5.43 to 9.23)
70–79	0.63 (0.33 to 1.18)	0.48 (0.30 to 0.77)	0.59 (0.43 to 0.80)	0.84 (0.66 to 1.07)	1.37 (1.07 to 1.74)	1.65 (1.22 to 2.22)	2.92 (2.05 to 4.17)	3.68 (2.37 to 5.72)
≥80	0.55 (0.17 to 1.84)	0.71 (0.33 to 1.54)	0.79 (0.47 to 1.34)	0.78 (0.50 to 1.23)	1.44 (0.93 to 2.24)	0.96 (0.49 to 1.86)	1.86 (0.86 to 4.00)	2.95 (1.28 to 6.79)

Patients with systolic BP of 130–139 mmHg served as referent category.

Table 3. Multivariable-adjusted hazard ratios and 95% confidence intervals of different outcomes, associated with different diastolic BP values in patients of different ages

Outcome per Age Category, yr	Diastolic BP				
	<50 mmHg (*n*=5896)	50–59 mmHg (*n*=34,045)	60–69 mmHg (*n*=110,117)	80–89 mmHg (*n*=57,306)	≥90 mmHg (*n*=13,305)
Mortality					
<50	0.42 (0.10 to 1.69)	1.23 (0.94 to 1.61)	1.28 (1.10 to 1.49)	1.10 (0.95 to 1.27)	1.24 (1.00 to 1.54)
50–59	1.48 (1.20 to 1.83)	1.33 (1.23 to 1.44)	1.21 (1.16 to 1.27)	0.92 (0.87 to 0.97)	0.92 (0.84 to 1.00)
60–69	1.30 (1.14 to 1.48)	1.38 (1.31 to 1.45)	1.16 (1.12 to 1.20)	0.91 (0.87 to 0.95)	0.99 (0.91 to 1.07)
70–79	1.33 (1.22 to 1.43)	1.24 (1.19 to 1.29)	1.12 (1.08 to 1.15)	0.97 (0.93 to 1.02)	1.09 (0.98 to 1.20)
≥80	1.23 (1.14 to 1.32)	1.16 (1.11 to 1.21)	1.07 (1.03 to 1.11)	1.04 (0.99 to 1.10)	1.15 (1.00 to 1.31)
Coronary heart disease					
<50	0.00 (0.00 to 0.00)	0.92 (0.40 to 2.16)	0.68 (0.43 to 1.08)	1.04 (0.78 to 1.40)	1.04 (0.68 to 1.60)
50–59	0.77 (0.34 to 1.73)	1.06 (0.84 to 1.34)	1.04 (0.93 to 1.16)	0.9 (0.81 to 1.00)	0.73 (0.61 to 0.88)
60–69	1.47 (0.97 to 2.24)	1.23 (1.05 to 1.46)	1.14 (1.04 to 1.26)	0.94 (0.85 to 1.05)	0.82 (0.67 to 1.00)
70–79	0.93 (0.62 to 1.39)	1.07 (0.90 to 1.26)	1.14 (1.02 to 1.27)	0.94 (0.81 to 1.09)	0.82 (0.59 to 1.16)
≥80	0.72 (0.44 to 1.18)	1.04 (0.84 to 1.29)	1.15 (0.99 to 1.34)	0.90 (0.71 to 1.14)	0.74 (0.39 to 1.41)
Stroke					
<50	0.00 (0.00 to 0.00)	0.84 (0.42 to 1.69)	0.92 (0.66 to 1.29)	0.81 (0.61 to 1.07)	0.99 (0.68 to 1.45)
50–59	1.01 (0.58 to 1.75)	1.12 (0.93 to 1.34)	1.10 (1.00 to 1.21)	0.95 (0.87 to 1.05)	0.87 (0.75 to 1.01)
60–69	1.13 (0.80 to 1.61)	1.08 (0.95 to 1.24)	1.13 (1.04 to 1.22)	0.94 (0.86 to 1.03)	0.98 (0.84 to 1.15)
70–79	1.13 (0.88 to 1.47)	1.11 (0.99 to 1.25)	1.12 (1.04 to 1.22)	0.84 (0.75 to 0.95)	1.05 (0.83 to 1.34)
≥80	0.73 (0.52 to 1.03)	1.00 (0.86 to 1.17)	0.99 (0.89 to 1.11)	0.86 (0.72 to 1.03)	0.93 (0.61 to 1.41)
ESRD					
<50	0.00 (0.00 to 0.00)	1.24 (0.57 to 2.70)	0.78 (0.52 to 1.18)	1.29 (1.01 to 1.65)	1.24 (0.90 to 1.70)
50–59	1.47 (0.61 to 3.55)	1.22 (0.90 to 1.65)	0.93 (0.80 to 1.08)	1.19 (1.06 to 1.33)	1.02 (0.87 to 1.21)
60–69	1.43 (0.63 to 3.22)	1.63 (1.27 to 2.10)	1.15 (0.99 to 1.34)	1.03 (0.88 to 1.20)	0.87 (0.67 to 1.13)
70–79	1.23 (0.62 to 2.43)	1.31 (0.98 to 1.75)	1.14 (0.93 to 1.39)	1.27 (0.99 to 1.63)	0.90 (0.53 to 1.55)
≥80	1.49 (0.65 to 3.40)	0.80 (0.47 to 1.38)	1.10 (0.77 to 1.58)	0.82 (0.45 to 1.49)	0.68 (0.16 to 2.86)

Patients with diastolic BP of 70–79 mmHg served as referent category.

between SBP and CHD in any age group among patients with weight loss or low BMI. DBP showed no consistent association with CHD overall or in subgroups (Figure 2, Table 3, Supplemental Figures 3, 6, and 7, Supplemental Table 2).

Incident Stroke

A total of 14,557 patients experienced an incident ischemic stroke (10.4 events/1000 PY; 95% CI, 10.2 to 10.6). Incident stroke rates were similar or lower in older versus younger individuals (Supplemental Tables 1 and 2). Age modified the association of SBP with stroke (*P* for interaction <0.001). Higher SBP was associated with linearly higher crude stroke rates in all age groups, with the lowest risk seen in patients with SBP<100 mmHg (Supplemental Figure 2, Supplemental Table 1). The multivariable-adjusted association of higher SBP with stroke was strongest among the youngest patients and was attenuated among older patients: The aHRs associated with SBP≥170 mmHg (compared with 130–139 mmHg) in patients <50, 50–59, 60–69, 70–79, and ≥80 years were 1.99 (95% CI, 1.05 to 3.79), 2.28 (95% CI, 1.82 to 2.86), 1.98 (95% CI, 1.59 to 2.46), 1.79 (95% CI, 1.41 to 2.27), and 1.26 (95% CI, 0.89 to 1.79), respectively (Figure 3, Table 2). DBP showed no association with stroke (Figure 3, Table 3, Supplemental Figure 3, Supplemental Table 2). Associations showed a similar pattern in all examined subgroups (Supplemental Figures 8 and 9).

Incident ESRD

A total of 5161 patients experienced ESRD (3.3 events/1000 PY; 95% CI, 3.2 to 3.3). ESRD rates were lower in older than younger individuals (Supplemental Tables 1 and 2). Age modified the association of SBP with ESRD (*P* for interaction <0.001). Higher SBP was associated with higher crude ESRD rates in all age groups, but with an attenuation in older patients (Supplemental Figure 2, Supplemental Table 1). Results were similar in multivariable-adjusted Cox models: The aHRs associated with SBP≥170 (compared with 130–139 mmHg) in patients <50, 50–59, 60–69, 70–79, and ≥80 years were 7.59 (95% CI, 4.89 to 11.79), 6.06 (95% CI, 4.93 to 7.47), 7.07 (95% CI, 5.42 to 9.22), 3.68 (95% CI, 2.37 to 5.72), and 2.95 (95% CI, 1.28 to 6.80), respectively (Figure 4, Table 2). The association of SBP with ESRD was linearly incremental in patients <80 years. While SBP≥170 mmHg was associated with significantly higher ESRD risk in patients ≥80 years, SBP<170 mmHg showed no consistent association with ESRD in this age group (Figure 4). DBP showed no association with ESRD (Figure 4, Table 3, Supplemental Figure 3, Supplemental Table 2). Associations showed a similar pattern in all examined subgroups (Supplemental Figures 10 and 11).



Figure 2. | Association of systolic BP (SBP) and diastolic BP (DBP) with incident coronary heart disease (first occurrence of a myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting), among 204,796 patients with incident CKD of different ages, in multivariable-adjusted Cox models. Models were adjusted for age, sex, race, marital status, per capita income, eGFR, prevalent comorbid conditions (hypertension, diabetes mellitus, coronary heart disease, congestive heart failure, peripheral artery disease, malignancies, liver disease, rheumatologic diseases, chronic lung disease, dementia, HIV/AIDS, depression, weight loss or low body mass index, and Charlson comorbidity index), number of antihypertensive medications prescribed at baseline, and baseline DBP (for SBP analyses) and baseline SBP (for DBP analyses). 95% CI, 95% confidence interval.

Discussion

We describe systematic differences across age groups in the relationship of SBP with outcomes in patients with incident CKD. Low DBP was associated with higher mortality, but DBP showed no consistent associations with cardiovascular outcomes. Our results reinforce the significant association of elevated SBP with all the studied outcomes but suggest weaker associations in the elderly, especially in patients aged ≥80 years. The best outcomes were seen with SBP of 120–139 mmHg in patients <80 years and of 120–159 mmHg in those ≥80 years. Our results concerning mortality are similar to the findings from a recent analysis of 21,015 patients with CKD from northern California and extend its findings to a larger population and to several other outcomes (33).

Current hypertension treatment guidelines recommend a target BP of <140/90 mmHg for most patients (13). The elderly are considered a special category (3), in part because of scarce clinical trial evidence in this population, and in part because of empirical and theoretical concerns over their tolerance of excessive BP lowering (34,35). The elderly may be more susceptible to deleterious effects of low BP as a result of age- and comorbidity-related alterations in hemodynamic autoregulatory mechanisms (15–19). This, however, cannot explain the diminished association of elevated SBP with outcomes in the elderly. A possible explanation could be the presence of competing risk from causes of death unrelated to BP (*e.g.*, malignancies or infections), which disproportionately affect the elderly, or adverse effects associated with the treatment of hypertension in the elderly (*e.g.*, falls) (36). Such effects may manifest most markedly in frail patients (37,38), a suggestion indirectly supported by the lack of associations in our subgroup analyses in individuals with weight loss or low BMI.

The attenuation of mortality risk associated with higher SBP in elderly patients described in our study echoes results from earlier studies reporting similarly weaker or absent associations of a multitude of traditional risk factors with mortality in elderly individuals, such as hypercholesterolemia (39), obesity (40), and comorbidity burden in general (41), as well as a more robust association of functional status with mortality (41). Furthermore, the association of cardiovascular diseases with mortality is also diminished in older populations (42,43), and risk factors such as hypertension, hypercholesterolemia, and obesity were less associated with incident CHD in previous studies (44). This supports our findings of relatively lower risk of cardiovascular event rates associated with higher SBP in the oldest age groups with CKD. Our findings of generally lower crude cardiovascular and renal event rates in older versus younger individuals also suggest that pathologic processes responsible for morbidity may be distinctly different in the elderly and could be affected by competing risk from the higher mortality seen in this group.



Figure 3. | Association of systolic BP (SBP) and diastolic BP (DBP) with incident ischemic stroke, among 301,569 patients with incident CKD of different ages, in multivariable-adjusted Cox models. Models were adjusted for age, sex, race, marital status, per capita income, eGFR, prevalent comorbid conditions (hypertension, diabetes mellitus, coronary heart disease, congestive heart failure, peripheral artery disease, malignancies, liver disease, rheumatologic diseases, chronic lung disease, dementia, HIV/AIDS, depression, weight loss or low body mass index, and Charlson comorbidity index), number of antihypertensive medications prescribed at baseline, and baseline DBP (for SBP analyses) and baseline SBP (for DBP analyses). 95% CI, 95% confidence interval.

Unfortunately, no guidelines address the conundrum of BP targets in elderly patients with CKD, even though most patients with CKD are elderly and their comorbidities make them susceptible to deleterious effects of low BP (15–19). In a previous analysis of veterans with prevalent CKD, we found that both SBP and DBP displayed a J-shaped association with all-cause mortality (45). We now extend these findings by demonstrating that elevated SBP is indeed associated with a multitude of adverse outcomes in all age groups, including the very old, but also that in the latter group these associations are subdued and that the ideal SBP could be extended to a level as high as 150 mmHg. Our findings therefore support current clinical guidelines, although the observational nature of our study does not allow the direct application of these results to clinical practice.

Our results do not provide an unequivocal answer to whether an SBP<130 mmHg is favorable or not. In a previous observational modeling of strict versus conventional BP control, patients with CKD whose SBP decreased to <120 mmHg after increased antihypertensive medication use experienced significantly higher mortality compared with those whose SBP decreased to 120–139 mmHg (46). The SPRINT study showed that treating SBP to a target of <120 mmHg (with an overall achieved SBP of 121.4 mmHg) versus <140 mmHg (with an achieved SBP of 136.2 mmHg) resulted in significantly lower all-cause mortality rate and nominally lower composite cardiovascular event rate in patients with CKD (14). These results support our findings regarding the lower risk of CHD and stroke associated with lower SBP but may be discordant with the J-shaped mortality seen in our and other observational studies, even though we have only detected statistically significantly higher mortality for patients with SBP<110 mmHg. SPRINT enrollees had markedly lower all-cause mortality rates compared with the populations examined in observational studies, which may be experiencing relatively more deaths unrelated to cardiovascular events. It is unclear whether they would derive a mortality benefit from SBP lowering to levels even stricter than those achieved in SPRINT.

Several limitations of our study should be acknowledged. This being an observational study, only associations, but no cause-and-effect relationships, can be established from it. Our cohort consisted mostly of men; hence, the findings may not be generalizable to women. We used multivariable-adjusted analyses, but the presence of residual confounders cannot be excluded. We used weight loss or low BMI in place of frailty because additional criteria for the standard definition of the latter (30) were not available in our database. We captured comorbidities and clinical events using diagnostic codes, not the more accurate adjudication procedures used in clinical trials. The lower cardiovascular and renal event rates seen in patients with low SBP in our cohort could have been affected by competing risk from higher mortality seen in these groups; hence, these associations need to be interpreted with proper caution, and without implying a protective effect from low SBP on such outcomes.



Figure 4. | Association of systolic BP (SBP) and diastolic BP (DBP) with incident ESRD (initiation of RRT or preemptive kidney transplantation), among 300,424 patients with incident CKD of different ages, in multivariable-adjusted Cox models. Models were adjusted for age, sex, race, marital status, per capita income, eGFR, prevalent comorbid conditions (hypertension, diabetes mellitus, coronary heart disease, congestive heart failure, peripheral artery disease, malignancies, liver disease, rheumatologic diseases, chronic lung disease, dementia, HIV/AIDS, depression, weight loss or low body mass index, and Charlson comorbidity index), number of antihypertensive medications prescribed at baseline, and baseline DBP (for SBP analyses) and baseline SBP (for DBP analyses). 95% CI, 95% confidence interval.

In conclusion, SBP>130–139 mmHg is associated with higher mortality and higher incidence of CHD, stroke, and ESRD in patients with CKD of all ages, but the strength of these associations diminishes with advanced age. DBP<70 mmHg is associated with higher mortality, but DBP shows no association with cardiovascular outcomes. Our results reinforce that treatment of hypertension in younger patients with CKD toward targets recommended by current clinical guidelines is paramount to improve outcomes in these patients. In very elderly patients with CKD, a more cautious BP-lowering strategy may be reasonable.

Acknowledgments

We thank Praveen Potukuchi, Bachelor of Pharmacy and Master of Science in Bioinformatics, Biomedical Sciences & Pharmaceutical Evaluation and Policy for help with preparing tables and figures. Author contributions: Study concept and design: all authors; acquisition of data: C.P.K. and J.L.L.; analysis and interpretation of data: C.P.K., J.L.L., A.Z.A.A., E.O.G., M.Z.M., and K.K.Z.; drafting of the manuscript and approval of the final version: C.P.K.; critical revision of the manuscript for important intellectual content and approval of the final version: all authors.

This study was supported by grant R01DK096920 to C.P.K. and K.K.Z. and is the result of work supported with resources and the use of facilities at the Memphis Veterans Affairs Medical Center and the Long Beach Veterans Affairs Medical Center. Support for Veterans Affairs/Centers for Medicare & Medicaid Services data is provided by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development, Veterans Affairs Information Resource Center (project numbers SDR 02-237 and 98-004).

C.P.K., E.O.G., B.M.W., A.M.H., and K.K.Z. are employees of the US Department of Veterans Affairs. Opinions expressed in this paper are those of the authors and do not necessarily represent the opinion of the Department of Veterans Affairs.

Disclosures

None.

References

1. Lawes CM, Vander Hoorn S, Rodgers A; International Society of Hypertension: Global burden of blood-pressure-related disease, 2001. *Lancet* 371: 1513–1518, 2008
2. Nwankwo T, Yoon SS, Burt V, Gu Q: Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011-2012. *NCHS Data Brief* 1–8, 2013
3. Kannel WB, Gordan T: Evaluation of cardiovascular risk in the elderly: The Framingham study. *Bull N Y Acad Med* 54: 573–591, 1978
4. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration: Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet* 360: 1903–1913, 2002

5. Langer RD, Criqui MH, Barrett-Connor EL, Klauber MR, Ganiats TG: Blood pressure change and survival after age 75. *Hypertension* 22: 551–559, 1993
6. Mattila K, Haavisto M, Rajala S, Heikinheimo R: Blood pressure and five year survival in the very old. *Br Med J (Clin Res Ed)* 296: 887–889, 1988
7. Rastas S, Pirttilä T, Viramo P, Verkkoniemi A, Halonen P, Juva K, Niinistö L, Mattila K, Länsimies E, Sulkava R: Association between blood pressure and survival over 9 years in a general population aged 85 and older. *J Am Geriatr Soc* 54: 912–918, 2006
8. Satish S, Freeman DH Jr, Ray L, Goodwin JS: The relationship between blood pressure and mortality in the oldest old. *J Am Geriatr Soc* 49: 367–374, 2001
9. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ; HYVET Study Group: Treatment of hypertension in patients 80 years of age or older. *N Engl J Med* 358: 1887–1898, 2008
10. Abramov D, Cheng H: Controversy in treating the oldest old with hypertension: Is the hypertension in the very elderly trial the final answer? *J Am Geriatr Soc* 57: 570–571, 2009
11. Goodwin JS: Embracing complexity: A consideration of hypertension in the very old. *J Gerontol A Biol Sci Med Sci* 58: 653–658, 2003
12. Gueyffier F, Bulpitt C, Boissel JP, Schron E, Ekbom T, Fagard R, Casiglia E, Kerlikowske K, Coope J; INDANA Group: Antihypertensive drugs in very old people: A subgroup meta-analysis of randomised controlled trials. *Lancet* 353: 793–796, 1999
13. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E: 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA* 311: 507–520, 2014
14. SPRINT Research GroupWright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT: A randomized trial of intensive versus standard blood-pressure control. *N Engl J Med* 373: 2103-2116, 2015
15. Bidani AK, Griffin KA, Williamson G, Wang X, Loutzenhiser R: Protective importance of the myogenic response in the renal circulation. *Hypertension* 54: 393–398, 2009
16. Ditscherlein G: Renal histopathology in hypertensive diabetic patients. *Hypertension* 7: II29–II32, 1985
17. Hayashi K, Epstein M, Saruta T: Altered myogenic responsiveness of the renal microvasculature in experimental hypertension. *J Hypertens* 14: 1387–1401, 1996
18. Palmer BF: Impaired renal autoregulation: Implications for the genesis of hypertension and hypertension-induced renal injury. *Am J Med Sci* 321: 388–400, 2001
19. Pelayo JC, Westcott JY: Impaired autoregulation of glomerular capillary hydrostatic pressure in the rat remnant nephron. *J Clin Invest* 88: 101–105, 1991
20. Kovesdy CP, Norris KC, Boulware LE, Lu JL, Ma JZ, Streja E, Molnar MZ, Kalantar-Zadeh K: Association of race with mortality and cardiovascular events in a large cohort of US veterans. *Circulation* 132: 1538–1548, 2015
21. Gosmanova EO, Lu JL, Streja E, Cushman WC, Kalantar-Zadeh K, Kovesdy CP: Association of medical treatment nonadherence with all-cause mortality in newly treated hypertensive US veterans. *Hypertension* 64: 951–957, 2014
22. Lu JL, Molnar MZ, Naseer A, Mikkelsen MK, Kalantar-Zadeh K, Kovesdy CP: Association of age and BMI with kidney function and mortality: a cohort study. *Lancet Diabetes Endocrinol* 3: 704–714, 2015
23. Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco ALM, De Jong PE, Griffith KE, Hemmelgarn BR, Iseki K, Lamb EJ, Levey AS, Riella MC, Shlipak MG, Wang H, White CT, Winearls CG: KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int Suppl* 3: 1–150, 2013
24. Lu JL, Kalantar-Zadeh K, Ma JZ, Quarles LD, Kovesdy CP: Association of body mass index with outcomes in patients with CKD. *J Am Soc Nephrol* 25: 2088–2096, 2014
25. Molnar MZ, Kalantar-Zadeh K, Lott EH, Lu JL, Malakauskas SM, Ma JZ, Quarles DL, Kovesdy CP: Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease. *J Am Coll Cardiol* 63: 650–658, 2014
26. Kovesdy CP, Lott EH, Lu JL, Malakauskas SM, Ma JZ, Molnar MZ, Kalantar-Zadeh K: Outcomes associated with microalbuminuria: Effect modification by chronic kidney disease. *J Am Coll Cardiol* 61: 1626–1633, 2013
27. Sohn MW, Zhang H, Arnold N, Stroupe K, Taylor BC, Wilt TJ, Hynes DM: Transition to the new race/ethnicity data collection standards in the Department of Veterans Affairs. *Popul Health Metr* 4: 7, 2006
28. Stroupe KT, Tarlov E, Zhang Q, Haywood T, Owens A, Hynes DM: Use of Medicare and DOD data for improving VA race data quality. *J Rehabil Res Dev* 47: 781–795, 2010
29. Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. *J Clin Epidemiol* 45: 613–619, 1992
30. Xue QL: The frailty syndrome: Definition and natural history. *Clin Geriatr Med* 27: 1–15, 2011
31. Sohn MW, Arnold N, Maynard C, Hynes DM: Accuracy and completeness of mortality data in the Department of Veterans Affairs. *Popul Health Metr* 4: 2, 2006
32. Royston P, Sauerbrei W: Interaction of treatment with a continuous variable: simulation study of power for several methods of analysis. *Stat Med* 33: 4695–4708, 2014
33. Weiss JW, Peters D, Yang X, Petrik A, Smith DH, Johnson ES, Thorp ML, Morris C, O'Hare AM: Systolic BP and Mortality in Older Adults with CKD. *Clin J Am Soc Nephrol* 10: 1553–1559, 2015
34. Franklin SS, Gustin W 4th, Wong ND, Larson MG, Weber MA, Kannel WB, Levy D: Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. *Circulation* 96: 308–315, 1997
35. Cupples LA, D'Agostino R: Some risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennial measurements: Framingham Heart Study, 30-year follow-up. In: The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease, Section 34, edited by Kannel WB, Wolf PA, Garnson RJ, Washington, DC, National Heart, Lung and Blood Institute, US Department of Health and Human Services Public Health Services, National Institutes of Health, 1987. NIH publication 87-2703
36. Tinetti ME, Han L, Lee DS, McAvay GJ, Peduzzi P, Gross CP, Zhou B, Lin H: Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults. *JAMA Intern Med* 174: 588–595, 2014
37. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA; Cardiovascular Health Study Collaborative Research Group: Frailty in older adults: Evidence for a phenotype. *J Gerontol A Biol Sci Med Sci* 56: M146–M156, 2001
38. Odden MC, Peralta CA, Haan MN, Covinsky KE: Rethinking the association of high blood pressure with mortality in elderly adults: The impact of frailty. *Arch Intern Med* 172: 1162–1168, 2012
39. Menotti A, Kromhout D, Nissinen A, Giampaoli S, Seccareccia F, Feskens E, Pekkanen J, Tervahauta M: Short-term all-cause mortality and its determinants in elderly male populations in Finland, The Netherlands, and Italy: The FINE Study. Finland, Italy, Netherlands Elderly Study. *Prev Med* 25: 319–326, 1996
40. Stevens J, Cai J, Pamuk ER, Williamson DF, Thun MJ, Wood JL: The effect of age on the association between body-mass index and mortality. *N Engl J Med* 338: 1–7, 1998
41. Lee SJ, Go AS, Lindquist K, Bertenthal D, Covinsky KE: Chronic conditions and mortality among the oldest old. *Am J Public Health* 98: 1209–1214, 2008
42. Nybo H, Petersen HC, Gaist D, Jeune B, Andersen K, McGue M, Vaupel JW, Christensen K: Predictors of mortality in 2,249 nonagenarians–the Danish 1905-Cohort Survey. *J Am Geriatr Soc* 51: 1365–1373, 2003
43. Ben-Ezra M, Shmotkin D: Predictors of mortality in the old-old in Israel: The Cross-sectional and Longitudinal Aging Study. *J Am Geriatr Soc* 54: 906–911, 2006
44. Abbott RD, Curb JD, Rodriguez BL, Masaki KH, Yano K, Schatz IJ, Ross GW, Petrovitch H: Age-related changes in risk factor effects

on the incidence of coronary heart disease. *Ann Epidemiol* 12: 173–181, 2002
45. Kovesdy CP, Bleyer AJ, Molnar MZ, Ma JZ, Sim JJ, Cushman WC, Quarles LD, Kalantar-Zadeh K: Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study. *Ann Intern Med* 159: 233–242, 2013
46. Kovesdy CP, Lu JL, Molnar MZ, Ma JZ, Canada RB, Streja E, Kalantar-Zadeh K, Bleyer AJ: Observational modeling of strict vs conventional blood pressure control in patients with chronic kidney disease. *JAMA Intern Med* 174: 1442–1449, 2014

Received: August 17, 2015 **Accepted:** February 1, 2016

Published online ahead of print. Publication date available at www.cjasn.org.

See related editorial, "The Continued Quest for Optimal BP Targets in Older Adults with Kidney Disease," on pages 753–755.

This article contains supplemental material online at http://cjasn.asnjournals.org/lookup/suppl/doi:10.2215/CJN.08660815/-/DCSupplemental.